ANN ARBOR, Mich.—NeuMoDx Molecular has expanded its portfolio with the launch of CE-IVD assays for hepatitis B virus  and hepatitis C virus. The company’s proprietary NeuDry reagents used with its systems are extremely robust and require no refrigeration. In addition, their unitized format boosts operating efficiency while minimizing waste. NeuMoDx offers an approach that can generate diagnostic results in roughly an hour, providing users with a continuous workflow for high-throughput sample processing.

 

“We are very pleased with our continued progress in expanding the menu on the first truly continuous random-access platform on the market,” said Dan Harma, chief commercial officer for NeuMoDx Molecular. “Laboratories around the world will be able to deliver high-quality results to clinicians and the patients they serve in a more rapid and efficient manner.”